Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe side-effect in colorectal cancer (CRC) patients. This study assessed the association between habitual dietary intake of magnesium or calcium and prevalence and severity of chronic CIPN in CRC patients receiving adjuvant chemotherapy. For this prospective cohort study, 196 CRC patients were considered. Magnesium and calcium intake was determined using a food frequency questionnaire at diagnosis, during and after chemotherapy. Chronic CIPN was assessed 12 months after diagnosis using the quality of life questionnaire CIPN20. Prevalence ratios were calculated to assess the association between magnesium or calcium intake and the prevalence of CIPN. Multivariable linear regression analysis was used to assess the association between magnesium or calcium intake and severity of CIPN. CIPN was reported by 160 (82%) patients. Magnesium intake during chemotherapy was statistically significantly associated with lower prevalence of CIPN (prevalence ratio (PR) 0.53, 95% confidence interval (CI) 0.32, 0.92). Furthermore, higher dietary intake of magnesium during (β −1.08, 95% CI −1.95, −0.22) and after chemotherapy (β −0.93, 95% CI −1.81, −0.06) was associated with less severe CIPN. No associations were found for calcium intake and the prevalence and severity of CIPN. To conclude, we observed an association between higher dietary magnesium intake and lower prevalence and severity of CIPN in CRC patients.

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients

“…Several drugs have been reported for treating CIPN. In these reports, calcium and magnesium, goshajinkigan, duloxetine, vitamin B12, pregabalin, and gabapentin were used [41][42][43][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62]. However, calcium/magnesium, goshajinkigan, and gabapentin were found to be ineffective at treating CIPN in the largest double-blind randomized controlled trials (RCTs) for each drug.…”

Possibility of magnesium supplementation for supportive treatment in patients with COVID-19

“…Higher magnesium intake in the diet is associated with a lower risk of colorectal tumors ( Wark et al, 2012 ). Prior research has demonstrated that high dietary magnesium intake may reduce the prevalence of chemotherapy-induced peripheral neuropathy and severity in patients with colorectal cancer ( Wesselink et al, 2018 ). Thus, eating magnesium-rich foods may be a new strategy for cancer prevention.…”

Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer

“…The time until Common Terminology Criteria for Adverse Events (CTCAE v4.0) grade 2 or higher CIPN was not significantly different between these three groups ( p value = 0.3383). In a 2018 prospective study written by Wesselink et al 39) , daily dietary intake of Ca/Mg was evaluated in 196 colorectal cancer patients. In that study, daily dietary intake of Mg during chemotherapy was associated with a lower occurrence and severity of CIPN (occurrence ratio: 0.53, 95% confidence interval (CI) −1.95, −0.22) 39) .…”